|
Market Closed -
NYSE
21:00:02 01/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 29.71 USD | +1.47% |
|
-1.36% | +24.67% |
Company Valuation: Arcus Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,843 | 1,497 | 1,430 | 1,363 | 2,948 | 3,728 | - | - |
| Change | - | -47.33% | -4.52% | -4.7% | 116.38% | 26.45% | - | - |
| Enterprise Value (EV) 1 | 2,344 | 488.4 | 670.7 | 384.6 | 2,066 | 3,288 | 3,626 | 3,423 |
| Change | - | -79.16% | 37.34% | -42.66% | 437.29% | 59.1% | 10.3% | -5.6% |
| P/E | 57x | -5.57x | -4.6x | -4.74x | -7.24x | -8.19x | -8.13x | -10.1x |
| PBR | - | 2.29x | 3.12x | 2.83x | 4.73x | 13.6x | -40.7x | 10.2x |
| PEG | - | 0x | -0.4x | 0.2x | -1.52x | -0.94x | -11.01x | 0.5x |
| Capitalization / Revenue | 7.43x | 13.4x | 12.2x | 5.28x | 11.9x | 47.4x | 71.6x | 20.9x |
| EV / Revenue | 6.12x | 4.36x | 5.73x | 1.49x | 8.37x | 41.8x | 69.6x | 19.2x |
| EV / EBITDA | 40.3x | -1.78x | -2.02x | -1.28x | -5.5x | -7.41x | -7.4x | -13x |
| EV / EBIT | 43.2x | -1.74x | -1.97x | -1.17x | -5.35x | -6.9x | -7.32x | -7.62x |
| EV / FCF | -8.3x | 1.13x | - | -2.19x | -4.27x | -17.4x | -9.53x | -13.3x |
| FCF Yield | -12% | 88.5% | - | -45.8% | -23.4% | -5.75% | -10.5% | -7.49% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.71 | -3.71 | -4.15 | -3.14 | -3.29 | -3.577 | -3.603 | -2.885 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 382.9 | 112 | 117 | 258 | 247 | 78.61 | 52.08 | 178.5 |
| EBITDA 1 | 58.09 | -274 | -332 | -300 | -376 | -443.4 | -490.2 | -264.1 |
| EBIT 1 | 54.25 | -280 | -340 | -330 | -386 | -476.7 | -495 | -449.1 |
| Net income 1 | 52.83 | -267 | -307 | -283 | -353 | -451 | -451.3 | -383.7 |
| Net Debt 1 | -499.3 | -1,009 | -759 | -978 | -882 | -440.6 | -102.2 | -305.4 |
| Reference price 2 | 40.47 | 20.68 | 19.10 | 14.89 | 23.83 | 29.28 | 29.28 | 29.28 |
| Nbr of stocks (in thousands) | 70,249 | 72,408 | 74,856 | 91,512 | 123,729 | 127,333 | - | - |
| Announcement Date | 23/02/22 | 28/02/23 | 21/02/24 | 25/02/25 | 25/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.19x | 41.82x | -7.41x | -.--% | 3.73B | |
| 33.86x | 6.04x | 17.97x | 0.95% | 49.81B | |
| -21.01x | 245.16x | -22.36x | -.--% | 44.06B | |
| 33.64x | 3.26x | 14.08x | -.--% | 42.99B | |
| 47.1x | 5.45x | 29.8x | -.--% | 40.88B | |
| 28.69x | 8.67x | 21.92x | 0.4% | 33.11B | |
| 33.78x | 5.53x | 25.14x | -.--% | 16.58B | |
| 24.18x | 2.1x | 9.1x | 1.11% | 14.63B | |
| 77.11x | 4.06x | 15.74x | -.--% | 13.76B | |
| Average | 27.68x | 35.79x | 11.55x | 0.27% | 28.84B | |
| Weighted average by Cap. | 27.07x | 46.57x | 12.32x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RCUS Stock
- Valuation Arcus Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
